TORRENT PHARMACEUTICALS LTD. - 500420 - Compliance As .Per Regulation 23(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Pursuant to regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, kindly find enclosed the disclosure of Related Paity Transactions for the half year ended on 3 l-Mar-22 TORRENT PHARMACEUTICALS LTD. - 500420 - Corporate Action-Board to consider Bonus Issue
Board has recommended to the members Issue of Bonus shares in the ratio of 1: 1 i.e. one equity share for each fully paid up equity share held as on record date fixed for the purpose TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Date of payment of Dividend
Board has recommended to the members A final dividend of Rs. 23/- (460%) per equity share of Rs. 5/- each including the special dividend of Rs. 15/~ per equity share. The final dividend amount, if declared by the Shareholders, is proposed to be paid/ dispatched on or around 4th August, 2022 TORRENT PHARMACEUTICALS LTD. - 500420 - Intimation Of Record Date Pursuant To Regulation 42 Of The Securities & Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 ("Listing Regulations")
Pursuant to Regulation 42 of Listing Regulations, the Company has fixed Monday, 6th June, 2022 as the Record Date for taking record of the Members of the Company entitled for the purpose of payment of final dividend for the year 2021-22, if declared by the Company. TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Raising of Funds
Recommended to the members to obtain enabling approval for issuance of Equity Shares including Convertible Bonds/ Debentures through Qualified Institutional Placement (QIP) and / or Depository Receipts or any other modes for an amount not exceeding Rs. 5,000 crores in the upcoming Annual General Meeting of the Company. TORRENT PHARMACEUTICALS LTD. - 500420 - Corporate Action-Board approves Dividend
Board has recommended to the members A final dividend of Rs. 23/- (460%) per equity share of Rs. 5/- each including the special dividend of Rs. 15/~ per equity share. TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Dividend Updates
Disclosure pursuant to Regulation 30 of (Listing Obligations and Disclosure Requirements), 2015, ("Listing Regulations") TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Investor Presentation
Presentation to analysts on Audited Financial Results for the quarter and year ended 31st March, 2022 TORRENT PHARMACEUTICALS LTD. - 500420 - Board Meeting Outcome for Disclosure Pursuant To Regulation 30 Read With Schedule III And Regulation 33 Of SEBI (Listing Obligations And Disclosure Requirements), 2015, ("Listing Regulations")
Disclosure pursuant to Regulation 30 read with Schedule III and Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), 2015, ("Listing Regulations") Q4FY22 Quarterly Result Announced for Torrent Pharmaceuticals Ltd.
Torrent Pharmaceuticals announced Q4FY22 results: Revenue at Rs 2,131 crore up by 10% Gross margins: 71%; EBITDA margins: 29%. EBITDA at Rs 612 crore was down by 1%. Exceptional item of Rs 485 crore, relates to impairment provision and costs related to discontinuation of liquid business in the US. Commenting on the Q4 results, Samir Mehta, Chairman, said: “We are pleased with the robust operational performance delivered during the quarter. The branded businesses contributed to 70% of total revenues in Q4 and grew by 15% with India and Brazil continuing on a strong footing. The US business registered sequential growth aided mainly by launch of a new product. While our EU business faced some headwinds, we remain optimistic that the cost efficiency measures being taken will bring us back to growth in this market in the coming quarters. We have taken a difficult decision of discontinuing our liquids business in the US. We believe the incremental investments required will exceed the potential economic benefits in this segment due to changing market conditions, as economics and competitive intensity have turned unfavorable compared to the time of conceptualization.” Result PDF